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Resectable left lower lobe non–small 
cell lung cancer with lymph node metastasis is 
related to unfavorable outcomes
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Abstract 
Background: Despite numerous previous studies, the consideration of tumor location as a prognostic factor in 
resectable non–small cell lung cancer (NSCLC) remains controversial. The present study analyzed the association 
between tumor location and clinical outcome in patients with resectable NSCLC who had undergone lobectomy with 
systematic lymphadenectomy and who had presented with varying nodal statuses.
Methods: The data from a cohort of 627 eligible patients treated in Sun Yat‑sen University Cancer Center between 
January 2000 and December 2008 were retrospectively collected, and the nodal statuses of patients with different 
tumor locations were compared. Cox proportional hazards regression model was used to determine the independent 
factors related to cancer‑specific survival (CSS).
Results: Multivariate analysis demonstrated that left lower lobe (LLL) tumors [hazard ratio (HR): 1.465, 95% confi‑
dence interval (CI) 1.090–1.969, P = 0.011], lymph node metastasis (HR: 2.742, 95% CI 2.145–3.507, P < 0.001), and a 
tumor size of >4 cm (HR: 1.474, 95% CI 1.151–1.888, P = 0.002) were three independent prognosticators in patients 
with resectable NSCLC. However, LLL tumors were associated only with CSS in node‑positive patients (HR: 1.528, 95% 
CI 1.015–2.301, P = 0.042), and a tumor size of >4 cm was the only independent risk predictor in the node‑negative 
subgroup (HR: 1.889, 95% CI 1.324–2.696, P < 0.001).
Conclusions: Tumor location is related to the long‑term CSS of NSCLC patients with lymph node metastasis. LLL 
tumors may be upstaged in node‑positive patients to facilitate an optimal treatment strategy.
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Background
Lung cancer is the first leading cause of cancer death in 
China [1] and around the world [2]. Despite the incor-
poration of standard multimodality therapies tailored by 
the staging system, non–small cell lung cancer (NSCLC) 
remains an aggressive disease with a dismal progno-
sis [3–5], highlighting the importance of seeking other 
prognostic factors and applying adjuvant or biological 
therapy for patients with poor prognosis.
Although tumor size and invasiveness have been used 
for many years in determining the T category of various 
cancers, tumor location is undervalued. Although this 
factor is not incorporated in the seventh edition of the 
International Association for the Study of Lung Cancer 
tumor-node-metastasis (TNM) staging system [6], tumor 
location has long been suggested as a potential, albeit con-
troversial, prognostic factor [7–11]. Previous investiga-
tors have found that non-upper lobe tumor location was 
an adverse prognostic factor for patients with stage I or III 
NSCLC [8–11]. However, a recent study by Puri et al. [12] 
indicated that tumor location does not predict survival of 
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patients with pathologic stages I and II NSCLC. Kudo et al. 
[13] also reported that tumor location influences only the 
long-term survival of NSCLC patients with lymph node 
metastasis. In addition, Whitson et  al. [14] found that, 
although tumor location is associated with lymph node 
yield, it is not an independent predictor of survival.
The conflicting results from previous studies may be 
partially due to the variation in the method by which 
the tumor locations, such as non-upper and upper, 
right- and left-sided, and left lower lobe (LLL) and non-
LLL tumor, were compared. Moreover, various surgical 
approaches, including pneumonectomy, wedge resec-
tion, and segmental resection, were used in their studies, 
possibly influencing the survival of patients with resect-
able NSCLC [15, 16]. In the present study, we therefore 
selected NSCLC patients who had undergone lobec-
tomy followed by systematic lymph node dissection and 
explored whether tumor lobe location was an independ-
ent prognostic factor for cancer-specific survival (CSS) 
based on nodal status.
Patients and methods
Patient selection
This study was approved by the Ethics Committee of the 
Sun Yat-sen University Cancer Center and was conducted 
using a database of 1578 consecutive patients who had 
undergone surgery for NSCLC at the Department of Tho-
racic Oncology between January 2000 and December 2008. 
Eligible patients included those with histologically proven 
NSCLC and had undergone complete resection, such as 
lobectomy (including bilobectomy) and systematic lymph 
node dissection (R0 resection). Patients who had under-
gone wedge resection, sleeve resection, segmentectomy, 
and pneumectomy and those with mediastinal lymph 
nodes (MLNs) being dissected at less than three stations 
were not included in the study. Patients who met any of 
the following criteria were also excluded: tumor located at 
a fissure and incorporating more than one lobe, the pres-
ence of distant metastasis before operation, neoadjuvant 
therapy before operation, previous or concurrent malig-
nancy, or postoperative death within 1 month. All patients 
provided written informed consent before surgery.
Therapeutic process
Thoracotomy or video-assisted thoracoscopy were per-
formed. The tumor location was marked during surgery 
as the right upper lobe (RUL), right non-upper lobe 
(RMLL), left upper lobe (LUL), or LLL. Following fixa-
tion in 10% neutral buffered formalin for approximately 
24 h at room temperature, the tumor size was measured 
and therefore the maximum diameter of the tumor was 
recorded. At least 6 stations of lymph nodes and no less 
than three stations of MLNs were dissected with the 
guidance of the Mountain/Dresler lymph node map [17]. 
The mediastinal lymphadenectomy procedure was per-
formed in accordance with the approach described in 
Allen’s study [18]. Each patient was staged according to 
the seventh edition of TNM classification [6].
Four to six cycles of cisplatin-based adjuvant chemo-
therapy were recommended to high-risk N0 and node-
positive patients undergoing surgery after 2004.
Follow‑up
Follow-up was generally carried out 1 month after sur-
gery, every 6 months for the first 3 years, and annually 
thereafter. The routine examinations included a physi-
cal examination, chest radiography, and ultrasound of 
the abdomen (including the liver, pancreas, spleen, kid-
ney, and adrenal glands). Chest and upper abdominal 
computed tomography and brain magnetic resonance 
imaging (MRI) were conducted every year. Bone scan, 
bronchoscopy, and vertebral MRI were performed only in 
symptomatic patients. Patients who were lost to follow-
up were censored at the last time of contact. The median 
length of follow-up for surviving patients was 84 months 
(range 1–163 months).
Statistical analysis
All statistical analyses were performed with SPSS version 
16.0 (SPSS, Chicago, IL, USA). Categorical variables were 
compared by using χ2 test or Fisher’s exact test, when 
applicable. The differences in the numerical variables 
between the two groups were analyzed using the Mann-
Whitney U test. Univariate and multivariate survival 
analyses with calculation of the hazard ratio (HR) were 
performed by using Cox proportional hazards regression 
model. Potential prognostic factors with a P value of less 
than 0.10 were entered into multivariate analyses. A step-
wise forward procedure was used to derive a final model 
of the variables. The CSS was defined as the duration 
from the date of the operation to either the date of death 
from NSCLC or the last follow-up (August 2, 2013). A 
significant difference was declared if the P value from a 
two-tailed test was less than 0.05.
Results
Demographic characteristics
A total of 627 patients were included in this study. Their 
clinicopathologic characteristics are summarized in 
Table  1. Histologically, 363 tumors were classified as 
adenocarcinoma, and 191 tumors were classified as squa-
mous cell carcinoma; the remaining 73 tumors were mis-
cellaneous types, including adenosquamous carcinoma, 
large cell carcinoma, and carcinoid carcinoma. A total of 
587 patients underwent a single lobectomy; the remain-
ing 40 patients underwent bilobectomy, including 8 
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lesions in the RUL, 6 lesions in the right median lobe, and 
26 lesions in the right lower lobe.
Tumor location and CSS in the entire cohort
During the follow-up period, 275 patients died, including 
12 from non-cancer-related causes, such as myocardial 
infarction, cerebral infarction, pneumonia, and vehicu-
lar accidents. The 5-year CSS rate of the entire cohort 
was 61.6%. The relationship between clinicopathologic 
characteristics and CSS is shown in Table  2. Univariate 
survival analysis indicated that tumors located in the 
non-upper lobe (P = 0.013), LLL tumors (P = 0.007), 
tumors with advanced T category (P = 0.001), lymph 
node metastasis (P < 0.001), a tumor size of >4 cm (P < 
0.001), the presence of pleural invasion (P = 0.015), a 
high histology grade (P = 0.006), and bilobectomy (P = 
0.044) were risk factors significantly associated with CSS. 
Multivariate analysis demonstrated that LLL (HR: 1.465, 
95% confidence interval CI 1.090–1.969, P = 0.011), 
lymph node metastasis (HR: 2.742, 95% CI 2.145–3.507, 
P < 0.001), and a tumor size of >4 cm (HR: 1.474, 95% CI 
1.151–1.888, P = 0.002) were independently associated 
with dismal CSS in patients with resected NSCLC.
Tumor location and CSS based on nodal status
We performed a sub-analysis of NSCLC patients strati-
fied in terms of nodal status. The relationship between 
the clinicopathologic characteristics and CSS in patients 
with or without lymph node metastasis was examined 
(Table 3). The 5-year CSS rate of node-negative patients 
was 73.8%. Univariate analysis indicated that gender (P = 
0.022), tumor location (upper vs. non-upper, P = 0.024; 
LLL vs. non-LLL, P = 0.038), T category (P = 0.001), 
pleural invasion (P = 0.029), tumor size (P < 0.001), and 
pathology (P = 0.013) were statistically associated with 
CSS. However, multivariate analysis demonstrated that 
the only independent risk predictor for CSS was a tumor 
size of >4 cm (HR: 1.889, 95% CI 1.324–2.696, P < 0.001, 
Fig.  1a). In node-positive patients, the 5-year CSS rate 
was 40.8%, and the presence of LLL tumors was the only 
factor significantly associated with unfavorable CSS (HR: 
1.528, 95% CI 1.015–2.301, P = 0.042, Fig. 1b).
The relationship between tumor location 
and clinicopathological factors
As shown in Table  4, the clinicopathologic characteris-
tics were compared between LLL and non-LLL tumors. 
After the patients were dichotomized into node-positive 
and node-negative groups, we found that LLL tumors 
associated with large tumor size (P < 0.001) and high 
histological grade (P = 0.023) in node-negative but not 
node-positive patients. Irrespective of nodal status, the 
association between LLL tumors and a smaller number 
of dissected MLNs was significant (P < 0.001). There were 
also significantly fewer dissected MLNs in left-sided than 
in right-sided tumors [node-negative: 5 (range 3–21) vs. 9 
(range 3–44), P < 0.001; node-positive: 5 (range 3–17) vs. 9 
(range 3–38), P < 0.001]. However, the difference between 
the number of MLNs dissected in upper and non-upper 
Table 1 Clinicopathologic characteristics of  the entire 
non–small cell lung cancer (NSCLC) patient cohort (n = 
627)
LUL left upper lobe, LLL left lower lobe, RUL right upper lobe, RMLL right 
non-upper lobe, AC adenocarcinoma, SCC squamous cell carcinoma, MLNs 
mediastinal lymph nodes






































No. of dissected MLNsa 7 (3, 44)
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tumors was not significant [node-negative: 7 (range 3–44) 
vs. 7 (range 3–29), P = 0.085; node-positive: 7 (range 3–38) 
vs. 7 (range 3–36), P = 0.772]. No significant differences 
in sex, age, T category, TNM stage, pathology, or pleural 
invasion were observed in any subgroups. However, in 
node-positive cases, more patients with LLL tumors than 
those with non-LLL tumors received adjuvant chemother-
apy (P = 0.050), whereas no significant difference existed 
in node-negative patients (P = 0.063).
Discussion
This study demonstrated that both non-upper and LLL 
tumors were unfavorable factors in CSS of patients with 
resectable NSCLC, as indicated by univariate analysis. 
However, only LLL tumors retained significance by mul-
tivariate analysis. The underlying reasons for this finding 
are not entirely clear, but we speculate that the lymphatic 
channel differs between lobes, likely resulting in differ-
ent prognoses. Lower lobe tumors have the tendency to 
Table 2 Univariate and multivariate analysis of prognostic variables for patients with resected NSCLC (n = 627)
LLL left lower lobe, non-LLL other lobes, AC adenocarcinoma, SCC squamous cell carcinoma, HR hazard ratio, CI confidence interval
a Cox proportional hazards regression analysis (forward stepwise)
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) Pa HR (95% CI) Pa
Sex (men vs. women) 0.827 (0.633–1.080) 0.162 – –
Age (≤60 years vs. >60 years) 1.076 (0.844–1.371) 0.556 – –
Tumor location
 (Left vs. right lobe) 0.904 (0.705–1.160) 0.428 – –
 (Upper vs. lower lobe) 1.362 (1.068–1.735) 0.013 – –
 (Non‑LLL vs. LLL) 1.493 (1.115–1.998) 0.007 1.465 (1.090–1.969) 0.011
T category (T1 vs. T2 vs. T3) 1.492 (1.173–1.898) 0.001 – –
N category (N0 vs. N1–2) 2.749 (2.152–3.512) 0.000 2.742 (2.145–3.507) <0.001
Pathology (AC vs. SCC vs. others) 1.103 (0.927–1.312) 0.269 – –
Histology grade (G1 vs. G2 vs. G3) 1.267 (1.071–1.499) 0.006 – –
Tumor size (≤4 vs. >4 cm) 1.617 (1.266–2.065) 0.000 1.474 (1.151–1.888) 0.002
Pleural invasion (no vs. yes) 1.627 (1.099–2.408) 0.015 – –
Resection (lobectomy vs. bilobectomy) 1.555 (1.013–2.386) 0.044 – –
Adjuvant chemotherapy (yes vs. no) 0.828 (0.644–1.065) 0.141 – –
Table 3 Univariate analysis for NSCLC patients with or without lymph node metastasis
NA not available. Other abbreviations as in Table  2
a Cox proportional hazards regression analysis (forward stepwise)
Characteristic Node‑negative patients (pN0) Node‑positive patients (pN1–2)
HR (95% CI) Pa HR (95% CI) Pa
Sex (men vs. women) 0.617 (0.409–0.932) 0.022 1.085 (0.761–1.546) 0.653
Age (≤60 vs. >60 years) 1.367 (0.959–1.949) 0.084 1.004 (0.713–1.413) 0.983
Tumor location
 (Left vs. right lobe) 0.980 (0.679–1.414) 0.913 0.857 (0.611–1.202) 0.372
 (Upper vs. lower lobe) 1.505 (1.055–2.146) 0.024 1.132 (0.812–1.578) 0.465
 (Non‑LLL vs. LLL) 1.554 (1.024–2.357) 0.038 1.528 (1.015–2.301) 0.042
T category (T1 vs. T2 vs. T3) 1.794 (1.284–2.507) 0.001 1.025 (0.694–1.515) 0.901
N category (N1 vs. N2) NA NA 1.049 (0.725–1.518) 0.801
Pathology (AC vs. SCC vs. others) 1.357 (1.066–1.727) 0.013 0.943 (0.732–1.213) 0.646
Histology grade (G1 vs. G2 vs. G3) 1.258 (0.994–1.592) 0.056 1.023 (0.797–1.314) 0.857
Tumor size (≤4 vs. >4 cm) 1.889 (1.324–2.696) <0.001 1.296 (0.924–1.816) 0.133
Pleural invasion (no vs. yes) 1.857 (1.064–3.242) 0.029 0.877 (0.505–1.525) 0.643
Resection (lobectomy vs. bilobectomy) 1.590 (0.774–3.265) 0.207 1.194 (0.699–2.040) 0.517
Adjuvant chemotherapy (yes vs. no) 1.490 (0.902–2.461) 0.120 1.241 (0.888–1.735) 0.207
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spread more frequently than upper lobe tumors to the 
subcarinal station, the passage of the hilar lymph nodes 
that connects with the contralateral nodes [19]. Hence, 
contralateral mediastinal drainage from the non-upper 
tumors may be more common, leading to unfavorable 
prognoses [20]. Moreover, left lung tumors spread to 
both the contralateral and ipsilateral lymph nodes with 
the same frequency [21], and the rate of occult metastasis 
to the right upper mediastinal nodes in left-sided NSCLC 
reached 72.7% [22]. Nohl-Oser et  al. [23] also demon-
strated that the highest metastatic rate to the contralat-
eral mediastinum was 40% in LLL tumors, compared 
with 22% in LUL and 7% in RLL tumors.
Interestingly, after stratification based on lymph node 
status, the unfavorable prognosis of LLL tumors was 
found to be affected by the presence or absence of nodal 
involvement. LLL tumors were independently associated 
with CSS only in patients with lymph node metastasis, 
whereas a tumor size of >4  cm is the only independent 
risk predictor in the node-negative subgroup. This find-
ing is consistent with that in a previous report by Kudo 
et al. [13], in which an influence of tumor location on the 
prognosis of patients with lymph node metastasis was 
also identified. It is tempting to attribute the dismal out-
come of LLL to the fact that the mediastinal lymph nodes 
are prone to metastasis. However, after calculating the 
mediastinal metastatic rate of LLL and non-LLL tumors 
in node-positive patients, we found that tumor location 
presented no association with the metastasis of the medi-
astinal lymph nodes. Therefore, the LLL tumor was an 
intrinsic prognostic factor in this subgroup of patients. 
The observed disparity may be attributed to the differ-
ent rates of occult metastasis in the contralateral nodes 
between node-positive and node-negative patients. In 
a recent study, Sakao et  al. [24] revealed that >50% of 
patients with ipsilateral mediastinal nodal involvement 
suffered from occult pN3 disease. LLL tumors may be 
easier to be understaged to pN3 disease in node-positive 
patients than in node-negative patients, leading to a more 
unfavorable prognosis.
Contralateral MLN dissection was not performed in the 
present study; thus, the uncertainty of the status of the 
contralateral MLNs casts doubt on our results. However, 
we performed a systematic MLN dissection using the 
approach described in Allen’s study [18], which has been 
recognized as a standard procedure for staging resected 
NSCLC. Significantly fewer MLNs were dissected in LLL 
tumors than in non-LLL tumors, potentially because the 
left upper mediastinal lymph nodes were not routinely 
dissected in left-sided tumors in the mediastinal lym-
phadenectomy procedure used. The results revealed that 
there was only a significant difference in the number of 
dissected MLNs between the left- and right-sided tumors 
and not between the upper and non-upper tumors.
Fig. 1 Kaplan–Meier survival analysis in patients with resectable non–small cell lung cancer (NSCLC). a The relationship between tumor size (≤4 
vs. >4 cm) and cancer‑specific survival in patients with resectable NSCLC without nodal involvement (P < 0.001); b the relationship between tumor 
location [left lower lobe (LLL) vs. non‑LLL] and cancer‑specific survival in patients with resectable NSCLC and nodal involvement (P = 0.042)
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In this study, LLL tumors were positively associ-
ated with large tumor size and high histology grade 
in node-negative patients. This association may be 
because the left heart shadow makes it difficult to find 
LLL tumors. Tumors of larger size and poor differentia-
tion are more invasive and progressive than smaller and 
well-differentiated ones. The close association between 
tumor location, size, and differentiation may explain why 
LLL tumors without lymph node metastasis are associ-
ated with poor survival in univariate analysis but not in 
multivariate analysis. However, in node-positive patients, 
tumor size and differentiation were not significantly 
Table 4 Relationship between tumor location and clinicopathologic factors of NSCLC patients
Abbreviations as in Tables 2 and 3
a The data are presented as medians followed by the range in the parenthese and analyzed by Mann-Whitney U test; other values are presented as the number of 
patients followed by the percentage in the parentheses
b Fisher’s exact test
c Comparison between patients with stages Ia/b and IIa/b NSCLC
d Comparison between patients with stages IIa/b and IIIa NSCLC
Characteristic Node‑negative patients (pN0) Node‑positive patients (pN1–2)
LLL (n = 66) Non‑LLL (n = 324) P LLL (n = 41) Non‑LLL (n = 196) P
Sex 0.702 0.264
 Men 47 (71.2) 223 (68.8) 25 (61.0) 137 (69.9)
 Women 19 (28.8) 101 (31.2) 16 (39.0) 59 (30.1)
Age 0.341 0.463
 ≤60 years 31 (47.0) 173 (53.4) 27 (65.9) 117 (59.7)
 >60 years 35 (53.0) 151 (46.6) 14 (34.1) 79 (40.3)
T category 0.291 1.000b
 T1 9 (13.6) 59 (18.2) 4 (9.8) 18 (9.2)
 T2 45 (68.2) 227 (70.1) 33 (80.5) 157 (80.1)
 T3 12 (18.2) 38 (11.7) 4 (9.8) 21 (10.7)
N category NA 0.170
 N1 0 0 15 (36.6) 51 (26.0)
 N2 0 0 26 (63.4) 145 (74.0)
TNM stage 0.445c 0.081d
 Ia/b 63 (95.5) 299 (92.3) 0 0
 IIa/b 3 (4.5) 25 (7.7) 15 (36.6) 46 (23.5)
 IIIa 0 0 26 (63.4) 150 (76.5)
Histology 0.260 1.000b
 AC 30 (45.5) 183 (56.5) 26 (63.4) 124 (63.3)
 SCC 27 (40.9) 105 (32.4) 10 (24.4) 49 (25.0)
 Others 9 (13.6) 36 (11.1) 5 (12.2) 23 (11.7)
Histology grade 0.023 0.256b
 G1 14 (21.2) 68 (21.0) 2 (4.9) 19 (9.7)
 G2 13 (19.7) 117 (36.1) 10 (24.4) 66 (33.7)
 G3 39 (59.1) 139 (42.9) 29 (70.7) 111 (56.6)
Tumor size <0.001 0.801
 ≤4 cm 29 (43.9) 230 (71.0) 27 (65.9) 125 (63.8)
 >4 cm 37 (56.1) 94 (29.0) 14 (34.1) 71 (36.2)
Pleural invasion 0.343 1.000b
 Yes 57 (86.4) 264 (81.5) 37 (90.2) 178 (90.8)
 No 9 (13.6) 60 (18.5) 4 (9.8) 18 (9.2)
Adjuvant chemotherapy 0.063 0.050
 Yes 9 (13.6) 78 (24.1) 30 (73.2) 111 (56.6)
 No 57 (86.4) 246 (75.9) 11 (26.8) 85 (43.4)
No. of MLNs dissecteda 4 (3, 17) 7.5 (3, 44) <0.001 5 (3, 14) 8 (3, 38) <0.001
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different between LLL and non-LLL tumors, making 
tumor location the only significant prognosticator.
The limitations of this study include its retrospec-
tive nature, the small sample size, and the long, 9-year 
time-span of the evaluated cases. The treatment strategy 
changed numerous times over these years, possibly ren-
dering the evaluation of the association between tumor 
location and prognosis more complicated. In this study, 
more node-positive patients with LLL tumors received 
postoperative chemotherapy than those with non-LLL 
tumors. Nevertheless, their CSS remains far from satis-
factory. Routine and standard adjuvant chemotherapy for 
node-positive patients was not performed until 2004, and 
this limitation makes a prospective study on multimodal-
ity therapy versus tumor location necessary.
Conclusions
This study revealed that the presence of LLL tumors was a 
robust unfavorable prognostic factor in resected NSCLC 
patients. However, its role accounted for node-positive 
but not node-negative patients, potentially because 
tumors located in the LLL might be upstaged in node-
positive patients. Further studies are needed to determine 
the optimal management strategy for this subgroup.
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